CandlesenseCandlesense
News/Companies/NBTX

NBTX News

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NBTX

(NASDAQ:NBTX) PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference:

September 2, 2025Investor
Read more →

Nanobiotix Provides Q1 2025 Operational Update; Says It Anticipates That The Cash And Cash Equivalents Of €39.8 Million As Of March 31, 2025, Will Fund Its Operations Into Mid-2026

NBTX

May 21, 2025
Read more →

Nanobiotix Highlights Median 13.3-Month Local Progression-Free Survival With JNJ-1900 (NBTXR3) After Radiation

NBTX

May 5, 2025
Read more →

Nanobiotix To Present Full Phase 1 Results Of NBTXR3 (JNJ-1900) In Locally Advanced Pancreatic Cancer At ESTRO 2025

NBTX

April 30, 2025
Read more →

Guggenheim Maintains Buy on Nanobiotix, Lowers Price Target to $8

NBTX

April 4, 2025
Read more →

Nanobiotix Reveals First Data From The Completed Dose Escalation Part Of Phase 1 Study Evaluating NBTXR3 (JNJ-1900) As A 2L+ Therapy for Patients With Locally Advanced NSCLC

NBTX

March 27, 2025
Read more →

NANOBIOTIX Presents Data From Two Phase 1 Studies Evaluating JNJ-1900 At European Lung Cancer Conference

NBTX

March 20, 2025
Read more →

NANOBIOTIX Q1 Cash And Cash Equivalents €58.9M As Of March 31, 2024

NBTX

May 22, 2024
Read more →

Nanobiotix Reports Updates For Global NBTXR3 Development Collaboration Highlighting Robust Pipeline And Pathway To Long-Term Growth

NBTX

May 21, 2024
Read more →